Literature DB >> 29303935

Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas.

Jenna Z Marcus, Merieme Klobocista, Rouzan G Karabakhtsian, Eric Prossnitz, Gary L Goldberg, Gloria S Huang.   

Abstract

OBJECTIVE: This study aimed to identify the hormonal receptor status in uterine adenosarcoma (AS) and uterine AS with sarcomatous overgrowth (AS + SO), including those with high-grade histologic features (nuclear pleomorphism, atypical mitoses, necrosis), with or without heterologous elements. Estrogen receptor (ER) status, including estrogen receptor α (ERα), estrogen receptor β (ERβ), and G protein-coupled estrogen receptor (GPER), and progesterone receptor (PgR) status were examined.
METHODS: From August 2001 to November 2013, 11 patients with histologic diagnosis of uterine AS were identified. Tumor tissue sections were stained for ERα, ERβ, GPER, and PgR and examined both for percentage of overall cells stained and for intensity of staining. Descriptive statistics were calculated using clinicopathologic data abstracted from the medical record.
RESULTS: Eight cases of AS and 3 cases of AS with high-grade features were identified. Seven of 8 tumor samples of AS showed strong or moderate intensity immunostaining for ERα; all AS + SO tumor samples showed minimal to no immunoreactivity for ERα. There was a significant decrease in ERα H scores in high-grade tumors when compared with AS (P = 0.01). Lower PgR H scores were observed in high-grade tumors compared with those in AS (P = 0.04). Estrogen receptor β immunostaining was variable, and GPER immunostaining was absent in the majority of tumor samples.
CONCLUSIONS: Higher expression of ERα and PgR was observed in AS when compared with those with AS + SO and high-grade features. Both tumor subtypes showed similar levels of ERβ and GPER expression, although significant differences in ERβ and GPER expression were not detected. In contrast to our previous findings in uterine carcinosarcoma, ERs ERβ and GPER do not seem to play a significant role in AS in this study.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29303935      PMCID: PMC6125779          DOI: 10.1097/IGC.0000000000001183

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  22 in total

Review 1.  The G protein-coupled estrogen receptor as a modulator of neoplastic transformation.

Authors:  Damian Jacenik; Adam I Cygankiewicz; Wanda M Krajewska
Journal:  Mol Cell Endocrinol       Date:  2016-04-21       Impact factor: 4.102

2.  Müllerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of müllerian mixed tumor.

Authors:  P B Clement; R E Scully
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

3.  Stage I uterine adenosarcoma: a report of six cases.

Authors:  T R Baker; M S Piver; S B Lele; Y Tsukada
Journal:  J Surg Oncol       Date:  1988-02       Impact factor: 3.454

Review 4.  International Union of Basic and Clinical Pharmacology. XCVII. G Protein-Coupled Estrogen Receptor and Its Pharmacologic Modulators.

Authors:  Eric R Prossnitz; Jeffrey B Arterburn
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 5.  The G-protein-coupled estrogen receptor GPER in health and disease.

Authors:  Eric R Prossnitz; Matthias Barton
Journal:  Nat Rev Endocrinol       Date:  2011-08-16       Impact factor: 43.330

6.  Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.

Authors:  T C Krivak; J D Seidman; J W McBroom; P J MacKoul; L M Aye; G S Rose
Journal:  Gynecol Oncol       Date:  2001-10       Impact factor: 5.482

7.  Extragenital adenosarcoma: a case report, review of the literature, and management discussion.

Authors:  Gloria S Huang; Rebecca C Arend; Antoinette Sakaris; Tiffany M Hebert; Gary L Goldberg
Journal:  Gynecol Oncol       Date:  2009-08-26       Impact factor: 5.482

8.  Management of uterine adenosarcomas with and without sarcomatous overgrowth.

Authors:  Edward J Tanner; Thomas Toussaint; Mario M Leitao; Martee L Hensley; Robert A Soslow; Ginger J Gardner; Elizabeth L Jewell
Journal:  Gynecol Oncol       Date:  2012-12-30       Impact factor: 5.482

9.  Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival.

Authors:  Brandon Bernard; Blaise A Clarke; Janet I Malowany; Jessica McAlpine; Cheng-Han Lee; Eshetu G Atenafu; Sarah Ferguson; Helen Mackay
Journal:  Gynecol Oncol       Date:  2013-10-14       Impact factor: 5.482

10.  G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth.

Authors:  Whitney K Petrie; Megan K Dennis; Chelin Hu; Donghai Dai; Jeffrey B Arterburn; Harriet O Smith; Helen J Hathaway; Eric R Prossnitz
Journal:  Obstet Gynecol Int       Date:  2013-11-27
View more
  3 in total

Review 1.  Current status of the adjuvant therapy in uterine sarcoma: A literature review.

Authors:  Alessandro Rizzo; Maria Abbondanza Pantaleo; Maristella Saponara; Margherita Nannini
Journal:  World J Clin Cases       Date:  2019-07-26       Impact factor: 1.337

2.  Advanced uterine adenosarcoma with sarcomatous overgrowth in a young woman: A case report.

Authors:  Bin Wang; Hua-Di Yang; Xin-He Shi; Hui Li
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

3.  Characteristic of Uterine Rhabdomyosarcoma by Algorithm of Potential Biomarkers for Uterine Mesenchymal Tumor.

Authors:  Saya Tamura; Takuma Hayashi; Tomoyuki Ichimura; Nobuo Yaegashi; Kaoru Abiko; Ikuo Konishi
Journal:  Curr Oncol       Date:  2022-03-28       Impact factor: 3.109

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.